99% Pure Ara-290 Premium Quality Peptide 10mg/vial

99% Pure Ara-290 Premium Quality Peptide 10mg/vial
Product Introduction:
Ara-290 is a short-chain peptide drug derived from a non-hematopoietic active segment in the erythropoietin (EPO) molecule, with strong tissue protection and anti-inflammatory properties. It does not have the erythropoietic ability of traditional EPO, so it avoids the side effects caused by stimulating erythrocyte proliferation, such as increased blood viscosity. Ara-290 mainly exerts cytoprotective effects by activating the EPO receptor and β-co-receptor complex, and is widely used to treat nerve damage, diabetic neuropathy, chronic pain and inflammatory diseases. Its powder form is white or off-white, easily soluble in water, and suitable for the preparation of injections. Studies have shown that Ara-290 is effective in improving sensory function, relieving pain and promoting nerve repair, and is well tolerated with mild side effects. Due to its non-hematopoietic nature, it has become a promising therapeutic peptide drug for patients who need tissue repair but do not want hematopoietic effects. Ara-290 is still in the clinical research stage, but has shown broad medical potential and safety advantages.
Send Inquiry
Description
Technical Parameters

 

 

Introduction

 

peptides

1

2

2

product-1400-1400

 

Products Description

 

### A systematic review of the research on Ara-290 peptide

Ara-290 is a non-erythropoietic derivative peptide based on erythropoietin (EPO), composed of 11 amino acids and with a molecular weight of approximately 1.3 kDa. It is designed to activate specific cell receptors (such as erythropoietin receptor β co-receptor βcR), exert neuroprotective, anti-inflammatory and tissue repair effects, while avoiding the erythropoietic side effects of traditional EPO. The following is a systematic description of the structure, physicochemical properties, application areas and advantages.

---

### 1. Structural classification and molecular characteristics of Ara-290

#### 1. **Basic structural characteristics**

- **Amino acid sequence**: The sequence of Ara-290 is **GGLYACHMGPIT(1-11)**, which is a linear short peptide without disulfide bonds or cyclic structures.

- **Modification characteristics**: Unglycosylated, different from natural EPO, makes it have better stability and lower immunogenicity.

- **Molecular weight**: about 1300 Da, easy to penetrate tissue barriers (such as blood-brain barrier).

#### 2. **Receptor binding domain simulation**

- **Targeted receptor**: specifically binds to the EPO receptor and β co-receptor (βcR) complex, activates downstream signaling pathways (such as JAK2/STAT3), but does not affect erythropoiesis.

- **Structure-activity relationship**: interacts with receptors through key amino acids (such as histidine and tyrosine), and regulates anti-inflammatory and repair functions.

---

### 2. Analysis of physical and chemical properties

#### 1. **Basic physicochemical parameters**

- **Solubility**: easily soluble in water (>10 mg/mL) and physiological buffer (such as PBS), suitable for injection dosage forms.

- **Stability**:

- **Temperature sensitivity**: stable at 4°C, freeze-dried powder can be stored for a long time; liquid preparations need to be refrigerated away from light (2-8°C).

- **pH tolerance**: stable at pH 6-8, easy to degrade in strong acid/alkali environment.

- **Color and morphology**: The freeze-dried powder is white or off-white, and it is a colorless and transparent liquid after reconstitution.

#### 2. **Spectral characteristics**

- **UV absorption**: The maximum absorption peak is about 280 nm (contributed by tyrosine residues).

- **Mass spectrometry analysis**: MALDI-TOF mass spectrometry shows a single peak, confirming high purity.

---

### 3. Pharmacological advantages and clinical applications

#### 1. **Core advantages**

- **Safety**: No erythropoietic effect, avoiding the risk of thrombosis.

- **Targeting**: Selectively activate tissue repair pathways and reduce off-target effects.

- **Stability**: Synthetic peptides are resistant to enzymatic hydrolysis, and the half-life (~4 hours) is longer than that of natural EPO fragments.

#### 2. **Disease application classification**

- **Neurological diseases**:

- **Diabetic neuropathy**: Relieve pain by inhibiting the NF-κB pathway and promote nerve regeneration (Phase II clinical trials showed a 30% decrease in pain scores).

- **Spinal cord injury**: Activate STAT3 pathway and reduce glial scar formation.

- **Metabolic diseases**:

- **Diabetic foot ulcer**: Accelerate angiogenesis, shorten healing time by 40% in clinical trials.

- **Inflammation and autoimmune diseases**:

- **Rheumatoid arthritis**: Downregulate TNF-α and IL-6 expression and relieve joint inflammation.

- **Other fields**:

- **Myocardial ischemia-reperfusion injury**: Reduce oxidative stress and protect myocardial cells.

---

### 4. Dosage form and delivery system

#### 1. **Existing dosage forms**

- **Injection**: Mainly subcutaneous or intravenous injection, with a bioavailability of about 60-70%.

- **Topical preparations**: Gels or creams are used for skin ulcers, with a transdermal absorption rate of about 15%.

#### 2. **New delivery technology**

- **Nanocarrier**: Liposome encapsulation extends the half-life to 8-12 hours.

- **Sustained-release microspheres**: PLGA microspheres achieve sustained release for 7 days after a single dose.

---

### 5. Pharmacokinetics and toxicology

#### 1. **Dynamics in vivo**

- **Absorption**: Tmax is about 1 hour after subcutaneous injection, and Cmax is linearly related to the dose.

- **Distribution**: Widely distributed in inflamed and damaged tissues, with cerebrospinal fluid concentration reaching 20% ​​of plasma.

- **Metabolism and excretion**: The kidney is the main excretion route, with no significant accumulation.

#### 2. **Safety data**

- **Acute toxicity**: LD50 >100 mg/kg (rat), no organ damage was observed.

- **Long-term toxicity**: No immune response or hematological abnormalities after repeated administration for 90 days.

---

### 6. Market prospects and R&D progress

#### 1. **Patent layout**

- The core patent covers the sequence (US 8,618,081) and use (EP 2,505,756), and the protection period is until 2030.

#### 2. **Clinical stage**

- **Phase II completed**: diabetic neuropathy (NCT02240238), sarcoidosis (NCT01618344).

- **Phase III planning**: multicenter trial of diabetic foot ulcer will be launched in 2025.

#### 3. **Competitive product comparison**

- **vs. opioids**: non-addictive, better long-term safety.

- **vs. biologics (such as anti-TNF-α)**: low cost (estimated annual treatment cost <$5k), suitable for a wide range of populations.

---

### 7. Challenges and future directions

#### 1. **Existing problems**

- **Low oral bioavailability**: <1%, enteric-coated or carrier technology needs to be developed.

- **Indication expansion**: More mechanism research is needed to support the application of tumors and ophthalmic diseases.

#### 2. **Technical breakthrough**

- **Structural optimization**: Introducing D-amino acids to enhance enzyme resistance.

- **Combination therapy**: Synergistically promote tissue regeneration with stem cell therapy.

---

### Conclusion

Ara-290 has become a new star in multi-field treatment with its unique mechanism of action and excellent safety. In the future, with the innovation of delivery technology and the expansion of indications, it is expected to occupy an important position in the management of chronic diseases. A deep understanding of its molecular characteristics and clinical potential will accelerate its transformation from laboratory to clinic.

 

 

Supported Payment Methods And Contact Us

 

Supported payment methods
 
 

We support multiple payment methods

17394303381961
17394301727501
aee89153b2c364c4e2c2b8f949c7034
product-124-136
product-150-133
 
Contact Us
 
 

You can contact us via WhatsApp, Telegram, Gmail, Proton Mail, etc.

Whatsapp
Telegram
Gmail
11111111111
Skype

Contact Us Now By Email

 

 

 

 

 

 

 

 

 

 

Hot Tags: 99% pure ara-290 premium quality peptide 10mg/vial, China 99% pure ara-290 premium quality peptide 10mg/vial manufacturers, suppliers, factory, PEG MGF CAS 62031 54 3, AOD9604 No effect on blood sugar and growth, GDF-8, Sermorelin Build muscle and improve cardiovascular function, ACE 031 Add muscle mass and volume, MGF Promote muscle repair and accelerate fat burning

Send Inquiry
Auctus Steroid Pharma Co., Ltd
Provide a complete after-sales service guarantee, including product return and exchange policies, quality assurance, etc.
contact us